SCLXW:NSD-Scilex Holding Company (USD)

COMMON STOCK | Drug Manufacturers - General |

Last Closing

USD 0.2499

Change

0.00 (0.00)%

Market Cap

N/A

Volume

750.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-04-28 )

Largest Industry Peers for Drug Manufacturers - General

Symbol Name Price(Change) Market Cap
AZN AstraZeneca PLC ADR

-2.39 (-3.18%)

USD 233.63B
AMGN Amgen Inc

-0.46 (-0.15%)

USD 169.66B
SNY Sanofi ADR

-0.38 (-0.71%)

USD 136.24B
GILD Gilead Sciences Inc

+0.21 (+0.24%)

USD 108.60B
BIIB Biogen Inc

-2.29 (-1.25%)

USD 26.65B
GRFS Grifols SA ADR

+0.57 (+6.95%)

USD 7.00B
AMRN Amarin Corporation PLC

-0.01 (-1.62%)

USD 0.26B
MIRA MIRA Pharmaceuticals, Inc. Com..

+0.47 (+27.17%)

USD 0.03B
SCLX Scilex Holding Company

-0.05 (-5.35%)

N/A

ETFs Containing SCLXW

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - General) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -30.58% 30% F 18% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -30.58% 30% F 18% F
Trailing 12 Months  
Capital Gain -85.04% 22% F 6% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return -85.04% 22% F 6% D-
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -7.83% 44% F 29% F
Dividend Return -7.83% 44% F 28% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 44.07% 22% F 39% F
Risk Adjusted Return -17.77% 44% F 32% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector